Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 373.33
OCLS's Cash to Debt is ranked higher than
88% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. OCLS: 373.33 )
OCLS' s 10-Year Cash to Debt Range
Min: 0.31   Max: No Debt
Current: 373.33

Equity to Asset 0.66
OCLS's Equity to Asset is ranked higher than
74% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. OCLS: 0.66 )
OCLS' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.73
Current: 0.66

-0.21
0.73
F-Score: 4
Z-Score: -13.35
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -55.64
OCLS's Operating margin (%) is ranked higher than
53% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. OCLS: -55.64 )
OCLS' s 10-Year Operating margin (%) Range
Min: -1202.95   Max: -7.35
Current: -55.64

-1202.95
-7.35
Net-margin (%) 5.90
OCLS's Net-margin (%) is ranked higher than
72% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. OCLS: 5.90 )
OCLS' s 10-Year Net-margin (%) Range
Min: -1219.03   Max: 27.33
Current: 5.9

-1219.03
27.33
ROE (%) 7.54
OCLS's ROE (%) is ranked higher than
76% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. OCLS: 7.54 )
OCLS' s 10-Year ROE (%) Range
Min: -1759.66   Max: 46.27
Current: 7.54

-1759.66
46.27
ROA (%) 4.68
OCLS's ROA (%) is ranked higher than
77% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. OCLS: 4.68 )
OCLS' s 10-Year ROA (%) Range
Min: -1518.83   Max: 22.39
Current: 4.68

-1518.83
22.39
ROC (Joel Greenblatt) (%) -767.20
OCLS's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. OCLS: -767.20 )
OCLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1665.34   Max: -358.75
Current: -767.2

-1665.34
-358.75
Revenue Growth (3Y)(%) -8.60
OCLS's Revenue Growth (3Y)(%) is ranked higher than
55% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. OCLS: -8.60 )
OCLS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -27.3   Max: 53.6
Current: -8.6

-27.3
53.6
» OCLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OCLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 4.10
OCLS's P/E(ttm) is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. OCLS: 4.10 )
OCLS' s 10-Year P/E(ttm) Range
Min: 1.86   Max: 11.44
Current: 4.1

1.86
11.44
PE(NRI) 3.90
OCLS's PE(NRI) is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. OCLS: 3.90 )
OCLS' s 10-Year PE(NRI) Range
Min: 1.86   Max: 11.44
Current: 3.9

1.86
11.44
P/B 0.90
OCLS's P/B is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. OCLS: 0.90 )
OCLS' s 10-Year P/B Range
Min: 0.88   Max: 264.25
Current: 0.9

0.88
264.25
P/S 0.52
OCLS's P/S is ranked higher than
97% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. OCLS: 0.52 )
OCLS' s 10-Year P/S Range
Min: 0.5   Max: 18.2
Current: 0.52

0.5
18.2
EV-to-EBIT -1.40
OCLS's EV-to-EBIT is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. OCLS: -1.40 )
OCLS' s 10-Year EV-to-EBIT Range
Min: -11.1   Max: -0.1
Current: -1.4

-11.1
-0.1
Current Ratio 1.48
OCLS's Current Ratio is ranked higher than
59% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. OCLS: 1.48 )
OCLS' s 10-Year Current Ratio Range
Min: 0.54   Max: 3.87
Current: 1.48

0.54
3.87
Quick Ratio 1.09
OCLS's Quick Ratio is ranked higher than
59% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. OCLS: 1.09 )
OCLS' s 10-Year Quick Ratio Range
Min: 0.5   Max: 3.65
Current: 1.09

0.5
3.65
Days Inventory 71.08
OCLS's Days Inventory is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. OCLS: 71.08 )
OCLS' s 10-Year Days Inventory Range
Min: 35.89   Max: 76.35
Current: 71.08

35.89
76.35
Days Sales Outstanding 40.42
OCLS's Days Sales Outstanding is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. OCLS: 40.42 )
OCLS' s 10-Year Days Sales Outstanding Range
Min: 40.32   Max: 151.99
Current: 40.42

40.32
151.99

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.90
OCLS's Price/Tangible Book is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. OCLS: 0.90 )
OCLS' s 10-Year Price/Tangible Book Range
Min: 1.51   Max: 183.75
Current: 0.9

1.51
183.75
Price/Median PS Value 0.10
OCLS's Price/Median PS Value is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. OCLS: 0.10 )
OCLS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 4.3
Current: 0.1

0.24
4.3
Price/Graham Number 0.60
OCLS's Price/Graham Number is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. OCLS: 0.60 )
OCLS' s 10-Year Price/Graham Number Range
Min: 0.47   Max: 1.08
Current: 0.6

0.47
1.08
Earnings Yield (Greenblatt) -72.30
OCLS's Earnings Yield (Greenblatt) is ranked lower than
61% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. OCLS: -72.30 )
OCLS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -204.1   Max: 0
Current: -72.3

-204.1
0

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 13 13
EPS($) -1.05 -1.05
EPS without NRI($) -1.05 -1.05

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:O8Z1.Germany,
Oculus Innovative Sciences Inc was incorporated under the laws of the State of California in April 1999 as Micromed Laboratories, Inc. In August 2001, it changed its name to Oculus Innovative Sciences, Inc. In December 2006, it reincorporated under the laws of the State of Delaware. The Company develops, manufactures and markets a family of tissue care products that cure infections and, through a separate mechanism of action, enhance healing while reducing the need for antibiotics. Infection is a serious potential complication in both chronic and acute wounds, and controlling infection is a critical step in wound healing. The Company's platform technology, called Microcyn(r), is a proprietary solution of electrically charged oxychlorine small molecules designed to treat a wide range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus, or VRE, in wounds, as well as Clostridium difficile (C. diff), a highly contagious bacteria spread by human contact. The Company's products compete with a variety of products used for wound cleaning, debriding and moistening, including sterile saline, and chlorhexadine-based products, and they also compete with a large number of prescription and over-the-counter products for the prevention and treatment of infections, including topical anti-infectives, such as Betadine, silver sulfadiazine, hydrogen peroxide, Dakin's solution and hypochlorous acid, and topical antibiotics, such as Neosporine, Mupirocin and Bacitracin. Government authorities in the United States at the federal, state and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical devices.
» More Articles for OCLS

Headlines

Articles On GuruFocus.com
Experience a Unique Realm Of Science Fiction With Sony’s Virtual Reality Headset Mar 12 2015 
?? Feb 27 2015 
Focus on New Technologies Can Drive Facebook's Growth Jan 22 2015 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 04 2011 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Nov 04 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 18,500 Shares Aug 09 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Oculus Innovative Sciences Inc. Reports Operating Results (10-Q) Feb 11 2010 
Oculus Innovative Sciences Inc. (OCLS) COO James J Schutz buys 20,000 Shares Dec 10 2009 

More From Other Websites
Oculus Innovative Sciences Banking Millions on Ruthigen-Pulmatrix Merger Mar 18 2015
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 16 2015
Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in... Mar 16 2015
Oculus Innovative Sciences Announces Sale of 350,000 Shares of Ruthigen Stock for $962,500 in... Mar 16 2015
OCULUS INNOVATIVE SCIENCES, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Mar 12 2015
Suddenly, everyone's making computers you strap to your face. Here's a rundown of all the big... Mar 07 2015
[$$] Google’s Android to Take On Facebook in Virtual Reality Mar 06 2015
I tried both of the two hottest virtual reality headsets this week — here's why Vive beats Oculus Mar 06 2015
I just had the most mind-blowing virtual reality experience ever Mar 04 2015
Oculus VR hires Google X exec Mary Lou Jepsen Mar 04 2015
Oculus VR hires Google X exec Mary Lou Jepsen Mar 03 2015
AMD's LiquidVR Technology Signals New Battleground For The GPU Wars Mar 03 2015
Sony Woos Game Makers to Bring Along Virtual Reality Mar 03 2015
Oculus Innovative Sciences Announces New Animal Healthcare Division and Launch of MicrocynAH®... Mar 03 2015
Google X exec jumps to Oculus — here's the talk she gave at Google when she was hired Mar 02 2015
HTC Takes on Sony With Headset That Lets You Roam Virtual Worlds Mar 02 2015
Sony Woos Game Makers to Ensure Demand for Virtual Reality Gear Mar 02 2015
HTC takes on Facebook in virtual reality wars Mar 01 2015
Oculus Innovative Sciences No One Trick Pony With Launch of New Animal Healthcare Division Feb 27 2015
Oculus Innovative Sciences Announces New Animal Healthcare Division and Launch of MicrocynAH(R)... Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK